Corporate News

INMUNOTEK listed in the 2020 edition of CEPYME500

cepyme500 2020December 2020

INMUNOTEK listed in CEPYME500, 2020 edition. This is an initiative of CEPYME (State Confederation of Small and Medium Enterprises) to identify, recognize and support the 500 leading companies in business growth in Spain. INMUNOTEK was already listed in 2017.
More info

European Patent Granted

EPODecember 2020

The European Patent Office has granted to INMUNOTEK the patent EP2982381B1. This refers to hypoallergenic neoglycoconjugates performed with non-oxidized mannan derived from S. cerevisiae to be used for the development of novel allergy vaccines targeting dendritic cells.
More info

CIEGE Seal for INMUNOTEK at Business Excellence

Sello IeENovember 2020

INMUNOTEK obtains the CIEGE Seal for excellence in business management for the second consecutive year. This Seal certifies excellent management over 57 indicators from 10 categories: solvency, profitability, growth, employment, internationalization, corporate social responsibility, customer satisfaction, innovation, commercial risk management and digitization.
More info

INMUNOTEK HELLAS new subsidiary

Logo ITK HellasNovember 2020

INMUNOTEK HELLAS is established in Athens, Greece, as a new European subsidiary of INMUNOTEK. With INMUNOTEK HELLAS, there are currently five subsidiaries of the INMUNOTEK Group around the world, and the second in Europe.
More info

INMUNOTEK Top-10 according to Pharma Tech Outlook

Top-ten PTO InmunotekOctober 2020

INMUNOTEK featured among the top-10 European immunotherapy providers by Pharma Tech Outlook, a specialized magazine in Pharma and Life Science technologies. The immunotherapy field covers different immune-based treatments for an increasing number of diseases. from allergies or cancer to autoimmune or infectious diseases.
More info